Peoples Bank OH cut its stake in Danaher Co. (NYSE:DHR – Free Report) by 14.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 885 shares of the conglomerate’s stock after selling 150 shares during the period. Peoples Bank OH’s holdings in Danaher were worth $203,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. FMR LLC boosted its stake in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. Van ECK Associates Corp boosted its stake in shares of Danaher by 6,862.7% during the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after buying an additional 916,513 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the last quarter. International Assets Investment Management LLC boosted its stake in shares of Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. boosted its stake in shares of Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after buying an additional 397,671 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Danaher
In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 11.10% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Analysis on Danaher
Danaher Stock Up 1.5 %
Danaher stock opened at $208.10 on Friday. The stock has a market cap of $150.31 billion, a P/E ratio of 39.41, a P/E/G ratio of 2.61 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $196.80 and a twelve month high of $281.70. The company’s 50-day moving average price is $227.21 and its two-hundred day moving average price is $247.52.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the company posted $2.09 EPS. As a group, analysts expect that Danaher Co. will post 7.67 EPS for the current year.
Danaher Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is a boost from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher’s dividend payout ratio (DPR) is currently 20.45%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Trading Stocks: RSI and Why it’s Useful
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.